Daiichi, Glycotope partner for cancer ADC

Daiichi Sankyo Co. Ltd. (Tokyo:4568) and Glycotope GmbH (Berlin, Germany) partnered to develop an antibody-drug conjugate (ADC) to treat cancer by combining Daiichi's ADC technology with Glycotope's PankoMab-GEX, a humanized IgG1 antibody targeting mucin 1 (MUC1; CD227) glycopeptide epitope...